（文章来源：证券日报） 证券日报网讯 8月13日晚间，海创药业发布公告称，公司于2025年8月13日召开第二届董事会第十一次 会议、第二届监事会第十次会议，审议通过了《关于首次公开发行股票部分募投项目子项目调整的议 案》。公司为了提高募集资金使用效率，拟对公司首次公开发行募集资金投资项目之"创新药研发项 目"中的部分子项目进行调整，"创新药研发项目"的拟投入募集资金保持不变。本次调整事项尚需提交 公司股东大会审议。 ...

Group 1 - The board of directors of Beijing Sunshine Nuohuo Pharmaceutical Research Co., Ltd. convened a meeting to discuss and approve changes to the use of special fundraising accounts and the establishment of new accounts [1][2] - The company agreed to change the purpose of existing fundraising accounts from various research projects to focus on "large model platform projects for peptide molecules" and "innovative drug research projects" [1][2] - New special fundraising accounts will be established by the company's subsidiaries for specific projects, ensuring that the funds are used solely for their intended purposes [1][2] Group 2 - The board approved an adjustment to the grant price of the 2025 restricted stock incentive plan from 22.78 yuan per share to 22.62 yuan per share due to the company's annual equity distribution [2][3] - This adjustment complies with relevant regulations and does not harm the interests of the company or its shareholders [2][3] - The voting results for the incentive plan adjustment showed unanimous support from the board members present [4]